Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

other similar words and terms. In particular, forward-looking statements include statements relating to the company's plans; its strategies; business prospects; anticipated growth; timing and level of savings achieved from the Productivity Transformation Program; prospective products or product approvals; trends in performance; anticipated timing of clinical trials and its impact on R&D spending; anticipated exclusivity periods; the potential of products and trending in therapeutic markets, including the cholesterol market; and statements about the timing and potential benefits of the proposed merger between Merck and Schering-Plough and other statements that are not historical facts. Actual results may vary materially from the company's forward-looking statements, and there are no guarantees about the performance of Schering-Plough stock or Schering-Plough's business. Schering-Plough does not assume the obligation to update any forward-looking statement.

A number of risks and uncertainties could cause results to differ materially from forward-looking statements, including, among other uncertainties, market viability of the company's (and the cholesterol joint venture's) marketed and pipeline products; market forces; economic factors such as interest rate and exchange rate fluctuations; the outcome of contingencies such as litigation and investigations; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the regulatory process (including product approvals, labeling and post-marketing actions); scientific developments relating to marketed products or pipeline projects; media and societal reaction to such developments; and the ability of Schering-Plough and Merck to obtain governmental and self-regulatory organization approvals of the merger on the proposed terms and schedule. For further details of these and other risks and uncertainties that may i
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... together supply chain risk management and resiliency practitioners with luminaries and thought leaders ... practices, and be recognized for their innovations and performance excellence. At that time ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.17 billion by 2018 ... The near future will bring Biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... people with Down syndrome, news from Elixirgen, LLC ... in the Science + Technology Park at Johns Hopkins, ... for people with Down syndrome and other chromosome disorders in ... Edwards syndrome aneuploidies in human cell cultures, " published ... to develop this technology into a treatment for the ...
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... 134% Increase In Revenues Year-Over-Year, CARLSBAD, Calif., Dec. ... laboratory service provider, today reported,revenues of $16.2 million for ... 134% over revenues of $6.9 million for the comparable ... 2007, the Company reported,revenues of $40.8 million, an increase ...
... and maintain successful partnerships, patient, recruitment expertise and ... CINCINNATI, Dec. 12 Kendle (Nasdaq: ... (CRO), today,announced it was named "Best CRO" at ... was selected from among leading global CROs by ...
... Odyssey Thera, Inc.,announced today that the United ... 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole animals: ... disease and gene therapy." This is the,twelfth patent ... patent describes a method for detecting protein-protein,interactions in ...
Cached Biology Technology:Genoptix Reports Strong Financial Results For Third Quarter 2007 2Genoptix Reports Strong Financial Results For Third Quarter 2007 3Genoptix Reports Strong Financial Results For Third Quarter 2007 4Genoptix Reports Strong Financial Results For Third Quarter 2007 5Genoptix Reports Strong Financial Results For Third Quarter 2007 6Genoptix Reports Strong Financial Results For Third Quarter 2007 7Genoptix Reports Strong Financial Results For Third Quarter 2007 8Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip 2Odyssey Thera Granted U.S. Patent for Animal Imaging 2
(Date:8/12/2015)... , Aug. 12, 2015  New research ... can attack Android phones to steal users, fingerprints. ... increasing availability of fingerprint scanners on mobile devices, ... concern. To secure biometrics on mobile devices, HYPR ... augment these convenient authentication systems with strong cryptographic ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... Caterpillars of two species of butterflies in Colorado and California ... broader range of temperatures in the past 40 years, suggesting ... more variable climate. The work, led by Joel ... represents a rare instance of how recent climate change affects ...
... Colo., USA - Can spaceborne radar help predict sinkholes? ... serpentinization affect sub-seafloor environments? Can OAE2 help us understand ... zones? When did vast landmasses first emerge above sea ... earthquake reveal about central Taiwan? How do you reconstruct ...
... a first-of-its-kind series of compounds possessing anti-human immunodeficiency ... target for potential HIV drug development and future ... today,s issue of the Journal of Virology ... 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2,-C-methylcytidine, were ...
Cached Biology News:Modern caterpillars feed at higher temperatures in response to climate change 2New geology research explores intriguing questions 2New geology research explores intriguing questions 3New geology research explores intriguing questions 4New geology research explores intriguing questions 5New geology research explores intriguing questions 6New geology research explores intriguing questions 7New geology research explores intriguing questions 8New geology research explores intriguing questions 9New anti-HIV drug target identified by University of Minnesota researchers 2
... is a direct antibiotic-based selection system for ... colony survival, eliminating the need for costly ... provides close to 100% accuracy in recombinant ... for robot colony picking. This cloning kit ...
...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Biology Products: